Your browser doesn't support javascript.
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.
Han, Qi; Guo, Mingyue; Zheng, Yue; Zhang, Ying; De, Yanshan; Xu, Changchang; Zhang, Lin; Sun, Ruru; Lv, Ying; Liang, Yan; Xu, Feng; Pang, Jiaojiao; Chen, Yuguo.
  • Han Q; Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
  • Guo M; Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China.
  • Zheng Y; Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
  • Zhang Y; The Key Laboratory of Cardiovascular Remodeling and Function Research, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong Universit
  • De Y; Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
  • Xu C; Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China.
  • Zhang L; Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
  • Sun R; The Key Laboratory of Cardiovascular Remodeling and Function Research, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong Universit
  • Lv Y; Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
  • Liang Y; Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China.
  • Xu F; Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
  • Pang J; The Key Laboratory of Cardiovascular Remodeling and Function Research, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong Universit
  • Chen Y; Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
Front Pharmacol ; 11: 615972, 2020.
Article in English | MEDLINE | ID: covidwho-1004690
Semantic information from SemMedBD (by NLM)
1. Signal Transduction Inhibitor TREATS COVID-19
Subject
Signal Transduction Inhibitor
Predicate
TREATS
Object
COVID-19
2. Signal Transduction Inhibitor TREATS Patients
Subject
Signal Transduction Inhibitor
Predicate
TREATS
Object
Patients
3. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
4. interleukin-6 ASSOCIATED_WITH COVID-19
Subject
interleukin-6
Predicate
ASSOCIATED_WITH
Object
COVID-19
5. COVID-19 PREDISPOSES Secondary Infections
Subject
COVID-19
Predicate
PREDISPOSES
Object
Secondary Infections
6. Secondary Infections NEG_PROCESS_OF Patients
Subject
Secondary Infections
Predicate
NEG_PROCESS_OF
Object
Patients
7. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
8. Signal Transduction Inhibitor TREATS COVID-19
Subject
Signal Transduction Inhibitor
Predicate
TREATS
Object
COVID-19
9. Signal Transduction Inhibitor TREATS Patients
Subject
Signal Transduction Inhibitor
Predicate
TREATS
Object
Patients
10. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
11. interleukin-6 ASSOCIATED_WITH COVID-19
Subject
interleukin-6
Predicate
ASSOCIATED_WITH
Object
COVID-19
12. COVID-19 PREDISPOSES Secondary Infections
Subject
COVID-19
Predicate
PREDISPOSES
Object
Secondary Infections
13. Secondary Infections NEG_PROCESS_OF Patients
Subject
Secondary Infections
Predicate
NEG_PROCESS_OF
Object
Patients
14. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
ABSTRACT

Background:

Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019 (COVID-19) because of its involvement in driving cytokine storm. This systematic review and meta-analysis aimed to assess the safety and efficacy of anti-IL-6 signaling (anti-IL6/IL-6R/JAK) agents on COVID-19 based on the current evidence.

Methods:

Studies were identified through systematic searches of PubMed, EMBASE, ISI Web of Science, Cochrane library, ongoing clinical trial registries (clinicaltrials.gov), and preprint servers (medRxiv, ChinaXiv) on August 10, 2020, as well as eligibility checks according to predefined selection criteria. Statistical analysis was performed using Review Manager (version 5.3) and STATA 12.0.

Results:

Thirty-one studies were included in the pooled analysis of mortality, and 12 studies were identified for the analysis of risk of secondary infections. For mortality analysis, 5630 COVID-19 cases including 2,132 treated patients and 3,498 controls were analyzed. Anti-IL-6 signaling agents plus standard of care (SOC) significantly decreased the mortality rate compared to SOC alone (pooled OR = 0.61, 95% CI 0.45-0.84, p = 0.002). For the analysis of secondary infection risk, 1,624 patients with COVID-19 including 639 treated patients and 985 controls were included, showing that anti-IL-6 signaling agents did not increase the rate of secondary infections (pooled OR = 1.21, 95% CI 0.70-2.08, p = 0.50). By contrast, for patients with critical COVID-19 disease, anti-IL-6 signaling agents failed to reduce mortality compared to SOC alone (pooled OR = 0.75, 95% CI 0.42-1.33, p = 0.33), but they tended to increase the risk of secondary infections (pooled OR = 1.85, 95% CI 0.95-3.61, p = 0.07). A blockade of IL-6 signaling failed to reduce the mechanical ventilation rate, ICU admission rate, or elevate the clinical improvement rate.

Conclusion:

IL-6 signaling inhibitors reduced the mortality rate without increasing secondary infections in patients with COVID-19 based on current studies. For patients with critical disease, IL-6 signaling inhibitors did not exhibit any benefit.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Evidence synthesis / Prognostic study / Randomized controlled trials / Reviews / Systematic review Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.615972

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Evidence synthesis / Prognostic study / Randomized controlled trials / Reviews / Systematic review Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.615972